期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
阿尔茨海默病脑内γ-氨基丁酸受体的变化
1
作者 张云帆 陈壮飞 付玉 《中国生物化学与分子生物学报》 CAS CSCD 北大核心 2023年第9期1275-1283,共9页
阿尔茨海默病(Alzheimer disease,AD)是一种进行性发展的神经系统退行性疾病,主要的临床病理特征为β-淀粉样蛋白(amyloidβ-protein,Aβ)斑块,tau过度磷酸化在细胞内形成神经元纤维缠结。目前,越来越多的证据表明,γ-氨基丁酸(gamma am... 阿尔茨海默病(Alzheimer disease,AD)是一种进行性发展的神经系统退行性疾病,主要的临床病理特征为β-淀粉样蛋白(amyloidβ-protein,Aβ)斑块,tau过度磷酸化在细胞内形成神经元纤维缠结。目前,越来越多的证据表明,γ-氨基丁酸(gamma aminobutyric acid,GABA)受体的变化与AD有着紧密的关系,有研究表明,GABA受体中各亚基在AD患者中表达水平有所变化。因此推测,GABA各亚基的变化可能与AD发病机制有关,但目前在临床,仍无较好地通过靶向治疗GABA受体来改善AD的方法。为了进一步了解GABA受体的变化与AD的关系,本文综述了脑内GABA受体在AD患者及动物模型中的变化,发现AD患者的GABA(A)受体亚基中出现了差异性表达。总结AlzheimerDataBase数据库AD中GABA受体各个亚基的改变,基于数据,我们发现少数几个GABA亚基发生了显著性变化。而证据显示,GABA受体的变化改变了脑内的神经活动,另有研究发现,通过GABA受体激动剂与拮抗剂治疗小鼠可以改善小鼠的认知能力。通过总结GABA受体在AD中的差异表达,希望为治疗AD提供更为准确的靶点。 展开更多
关键词 阿尔茨海默病 Γ-氨基丁酸受体 γ-氨基丁酸受体激动剂 γ-氨基丁酸受体拮抗剂
下载PDF
Electroacupuncture-induced activation of GABAergic system alleviates airway inflammation in asthma model by suppressing TLR4/MyD88/NF-κB signaling pathway 被引量:4
2
作者 Ruisong Gong Xiaowen Liu Jing Zhao 《Chinese Medical Journal》 SCIE CAS CSCD 2023年第4期451-460,共10页
Background: Electroacupuncture (EA) has been shown to attenuate airway inflammation in asthmatic mice;however, the underlying mechanism is not fully understood. Studies have shown that EA can significantly increase th... Background: Electroacupuncture (EA) has been shown to attenuate airway inflammation in asthmatic mice;however, the underlying mechanism is not fully understood. Studies have shown that EA can significantly increase the inhibitory neurotransmitter γ-aminobutyric acid (GABA) content in mice, and can also increase the expression level of GABA type A receptor (GABAAR). Furthermore, activating GABAAR may relieve inflammation in asthma by suppressing toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear factor-kappa B (NF-κB) signaling pathway. Therefore, this study aimed to investigate the role of GABAergic system and TLR4/MyD88/NF-κB signaling pathway in asthmatic mice treated with EA. Methods: A mouse model of asthma was established, and a series of methods including Western blot and histological staining assessment were employed to detect the level of GABA, and expressions of GABAAR and TLR4/MyD88/NF-κB in lung tissue. In addition, GABAAR antagonist was used to further validate the role and mechanism of GABAergic system in mediating the therapeutic effect of EA in asthma. Results: The mouse model of asthma was established successfully, and EA was verified to alleviate airway inflammation in asthmatic mice. The release of GABA and the expression of GABAAR were significantly increased in asthmatic mice treated with EA compared with untreated asthmatic mice ( P < 0.01), and the TLR4/MyD88/NF-κB signaling pathway was down-regulated. Moreover, inhibition of GABAAR attenuated the beneficial effects of EA in asthma, including the regulation of airway resistance and inflammation, as well as the inhibitory effects on TLR4/MyD88/NF-κB signaling pathway. Conclusion: Our findings suggest that GABAergic system may be involved in mediating the therapeutic effect of EA in asthma, possibly by suppressing the TLR4/MyD88/NF-κB signaling pathway. 展开更多
关键词 ELECTROACUPUNCTURE ASTHMA gamma-aminobutyric acid receptors gaba Toll-like receptor 4 Myeloid differentiation factor 88 NF-kappa B
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部